Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Fixed-dose regimes ‘modestly’ lower risk of HIV treatment failure

New research compares treatment outcomes of single versus multiple tablet regimes, raising questions around cost-effectiveness.

Published
Less than 1 hour ago
From
Avert
Baseline CD4 count biggest factor in long-term immune system improvements after starting HIV therapy

Pre-treatment CD4 cell count is the most important factor in immune recovery following the initiation of combination antiretroviral therapy (cART), according to the results of a large observation

Published
14 December 2017
By
Michael Carter
South Africa’s HIV treatment programme: a phoenix rising from the ashes?

In our most recent modelling study, published this week in PLoS Medicine, we have attempted to look back on what the ART programme has achieved to date – and what could have been achieved. It’s too soon to say whether progress reducing AIDS deaths has stalled, but the early signs suggest that this may be the new reality in the post-2014 period.

Published
13 December 2017
From
Ground Up
Fingerprints of Russian Disinformation: From AIDS to Fake News

Called Operation Infektion by the East German foreign intelligence service, the 1980s disinformation campaign seeded a conspiracy theory that the virus that causes AIDS was the product of biological weapons experiments conducted by the United States.

Published
13 December 2017
From
New York Times
Transition to dolutegravir cost-effective in LMICs with high HIV drug resistance

In low- and middle-income countries, resistance to non-nucleoside reverse transcriptase inhibitors, or NNRTIs, is nearing and exceeding 10% in patients with HIV who are initiating or reinitiating first-line ART, according to recent data. A new modeling study showed that transitioning first-line ART from NNRTIs to dolutegravir may be a cost-effective way to reverse this increasing trend in resistance.

Published
13 December 2017
From
Healio
Frontiers of HIV Research: The Man Who Was Nearly Cured

“The whole excitement around Clark is that we were able to initiate therapy so early that we were hoping to prevent the establishing of latency,” says Deeks. “But it did not happen. We got close; we may have been off by a day or two. We did not achieve a real cure.”

Published
13 December 2017
From
KQED
The challenge of defining an HIV cure

What does a cure for HIV infection look like? It sounds like a simple question, but because of the way the virus can persist in the body, there are significant challenges associated with trying to define if a cure might have been achieved. As the research effort to develop a safe, effective, broadly accessible HIV cure expands, the issue of how to measure success remains central, and is important to understand.

Published
12 December 2017
From
Positively Aware
Could we safely reduce the frequency of treatments for HIV-positive people?

Most HIV-positive people in France under treatment take a daily dose of antiviral drugs for life. However, a major trial is currently underway that may confirm that patients could omit several days of treatment a week without risk to their health.

Published
08 December 2017
From
The Conversation
HIV drug resistance now high enough to trigger a change in first-line treatment in eastern and southern Africa

HIV drug resistance is increasing rapidly in southern and eastern Africa and Latin America and, as a result, it may soon be necessary to change the

Published
04 December 2017
By
Keith Alcorn
HIV ‘cure’ based on one patient? Here’s what you need to know

Headlines today raise hope that a cancer drug could “cure” HIV infection. But this potential cure is based on results from just a single man whose reservoir of dormant HIV-infected cells went down after treatment with the cancer drug nivolumab.

Published
04 December 2017
From
Health News Review
← First12345...457Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.